Dongzi Lin1, Wei Wang1, Feng Qiu2, Yumei Li3, Xiaolin Yu3, Bingyao Lin1, Yinwen Chen3, Chunyan Lei1, Yan Ma1, Jincheng Zeng4, Jie Zhou1. 1. Department of Laboratory Medicine, Foshan Forth People's Hospital, Foshan 528041, China. 2. Department of Laboratory Medicine, Nanhai Hospital, Southern Medical University, Foshan 528244, China. 3. Department of Laboratory Medicine, Dongguan Sixth People's Hospital, Dongguan 523008, China. 4. Dongguan Key Laboratory of Medical Bioactive Molecular Developmental and Translational Research, Guangdong Medical University, Dongguan 523808, China.
Abstract
OBJECTIVE: To screen new serum metabolic biomarkers for different drug resistance profiles of pulmonary tuberculosis (TB) and explore their mechanisms and functions. METHODS: We collected serum samples from TB patients with drug sensitivity (DS), monoresistance to isoniazid (MR-INH), monoresistance to rifampin (MR-RFP), multidrug resistance (MDR), and polyresistance (PR). The metabolites in the serum samples were extracted by oscillatory and deproteinization for LC-MS/MS analysis, and the results were normalized by Pareto-scaling method and analyzed using Metaboanalyst 4.0 software to identify the differential metabolites. The differential metabolites were characterized by function enrichment and co-expression analysis to explore their function and possible pathological mechanisms. RESULTS: Compared with the DS group, 286 abnormally expressed metabolites were identified in MR-INH group, 362 in MR-RPF group, 277 in MDR group and 1208 in PR group by LC-MS/MS analysis. Acetylagmatine (P < 0.05), aminopentol (P < 0.05), and tetracosanyl oleate (P < 0.05) in MR-INH group; Ala His Pro Thr (P < 0.001) and glycinoprenol-9 (P < 0.05) in MR-RFP group; trimethylamine (P < 0.05), penaresidin A (P < 0.05), and verazine (P < 0.05) in MDR group; and PIP (18:1(11Z)/ 18:3(6Z, 9Z, 12Z)) (P < 0.001), Pro Arg Trp Tyr (P < 0.001), N-methyldioctylamine (P < 0.001), and phytolaccoside E (P < 0.05) in PR group all showed significant differential expressions. Significant differential expressions of phthalic acid mono-2-ethylhexyl ester (P < 0.05) and eicosanoyl-EA (P < 0.05) were found in all the drug resistant groups as compared with DS group. CONCLUSIONS: Acetylagmatine, aminopentol, tetracosanyl oleate, Ala His Pro Thr, glycinoprenol-9, trimethylamine, penaresidin A, verazine, PIP(18:1(11Z)/18:3(6Z, 9Z, 12Z)), Pro Arg Trp Tyr, N-methyldioctylamine, phytolaccoside E, phthalic acid mono-2-ethylhexyl ester, and eicosanoyl-EA are potentially new biomarkers that indicate monoresistance, multi-drug resistance and polyresistance of Mycobacterium tuberculosis. The combined use of these biomarkers potentially allows for assessment of drug resistance in TB and enhances the diagnostic sensitivity and specificity.
OBJECTIVE: To screen new serum metabolic biomarkers for different drug resistance profiles of pulmonary tuberculosis (TB) and explore their mechanisms and functions. METHODS: We collected serum samples from TB patients with drug sensitivity (DS), monoresistance to isoniazid (MR-INH), monoresistance to rifampin (MR-RFP), multidrug resistance (MDR), and polyresistance (PR). The metabolites in the serum samples were extracted by oscillatory and deproteinization for LC-MS/MS analysis, and the results were normalized by Pareto-scaling method and analyzed using Metaboanalyst 4.0 software to identify the differential metabolites. The differential metabolites were characterized by function enrichment and co-expression analysis to explore their function and possible pathological mechanisms. RESULTS: Compared with the DS group, 286 abnormally expressed metabolites were identified in MR-INH group, 362 in MR-RPF group, 277 in MDR group and 1208 in PR group by LC-MS/MS analysis. Acetylagmatine (P < 0.05), aminopentol (P < 0.05), and tetracosanyl oleate (P < 0.05) in MR-INH group; Ala His Pro Thr (P < 0.001) and glycinoprenol-9 (P < 0.05) in MR-RFP group; trimethylamine (P < 0.05), penaresidin A (P < 0.05), and verazine (P < 0.05) in MDR group; and PIP (18:1(11Z)/ 18:3(6Z, 9Z, 12Z)) (P < 0.001), Pro Arg Trp Tyr (P < 0.001), N-methyldioctylamine (P < 0.001), and phytolaccoside E (P < 0.05) in PR group all showed significant differential expressions. Significant differential expressions of phthalic acid mono-2-ethylhexyl ester (P < 0.05) and eicosanoyl-EA (P < 0.05) were found in all the drug resistant groups as compared with DS group. CONCLUSIONS: Acetylagmatine, aminopentol, tetracosanyl oleate, Ala His Pro Thr, glycinoprenol-9, trimethylamine, penaresidin A, verazine, PIP(18:1(11Z)/18:3(6Z, 9Z, 12Z)), Pro Arg Trp Tyr, N-methyldioctylamine, phytolaccoside E, phthalic acid mono-2-ethylhexyl ester, and eicosanoyl-EA are potentially new biomarkers that indicate monoresistance, multi-drug resistance and polyresistance of Mycobacterium tuberculosis. The combined use of these biomarkers potentially allows for assessment of drug resistance in TB and enhances the diagnostic sensitivity and specificity.
Entities:
Keywords:
LC-MS/MS; drug resistance; metabolic markers; pulmonary tuberculosis; serum
Authors: I Takenami; C C de Oliveira; J D Petrilli; A Machado; L W Riley; S Arruda Journal: Int J Tuberc Lung Dis Date: 2018-09-01 Impact factor: 2.373
Authors: D Kalo; A Vitorino Carvalho; C Archilla; V Duranthon; M Moroldo; Y Levin; M Kupervaser; Y Smith; Z Roth Journal: Toxicology Date: 2019-05-04 Impact factor: 4.221
Authors: Susanna K P Lau; Ching-Wan Lam; Shirly O T Curreem; Kim-Chung Lee; Candy C Y Lau; Wang-Ngai Chow; Antonio H Y Ngan; Kelvin K W To; Jasper F W Chan; Ivan F N Hung; Wing-Cheong Yam; Kwok-Yung Yuen; Patrick C Y Woo Journal: Emerg Microbes Infect Date: 2015-01-28 Impact factor: 7.163
Authors: Jody Phelan; Denise M O'Sullivan; Diana Machado; Jorge Ramos; Alexandra S Whale; Justin O'Grady; Keertan Dheda; Susana Campino; Ruth McNerney; Miguel Viveiros; Jim F Huggett; Taane G Clark Journal: Genome Med Date: 2016-12-22 Impact factor: 11.117
Authors: January Weiner; Jeroen Maertzdorf; Jayne S Sutherland; Fergal J Duffy; Ethan Thompson; Sara Suliman; Gayle McEwen; Bonnie Thiel; Shreemanta K Parida; Joanna Zyla; Willem A Hanekom; Robert P Mohney; W Henry Boom; Harriet Mayanja-Kizza; Rawleigh Howe; Hazel M Dockrell; Tom H M Ottenhoff; Thomas J Scriba; Daniel E Zak; Gerhard Walzl; Stefan H E Kaufmann Journal: Nat Commun Date: 2018-12-06 Impact factor: 14.919
Authors: Jeffrey M Collins; Douglas I Walker; Dean P Jones; Nestani Tukvadze; Ken H Liu; ViLinh T Tran; Karan Uppal; Jennifer K Frediani; Kirk A Easley; Neeta Shenvi; Manoj Khadka; Eric A Ortlund; Russell R Kempker; Henry M Blumberg; Thomas R Ziegler Journal: PLoS One Date: 2018-10-11 Impact factor: 3.240